Bis-furan derivatives as transthyretin (TTR) stabilizers and amyloid inhibitors for the treatment of familial amyloid polyneuropathy (FAP)

A compound of Formula (I):

• or pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or prodrug thereof, wherein:
• —Y is —CH═CH— or —CH2—CH2—;
• R1 is H or —CH3;
• R2 is —ORa, —C(═O)ORa, —S(═O)2NHRa, —S(═O)2ORa, —P(═O)NH2(ORa), —C(═O)N(Ra)2, —C(═O)NHORa, or —CHN4 (tetrazolyl);
• R3 is H or —CH3;
• R4 is H, —OH, Halogen, —CH3, or —OCH3;
• R5 is H, F, —CN, —SH, —ORa, —S(═O)2NHRa, —S(═O)2ORa, —P(═O)NH2(ORa), —C(═O)NHORa, or —CHN4 (tetrazolyl);
• R6 is H, —OH, Halogen, —CH3, or —OCH3;
• and
• each instance of Ra is independently H, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, or an oxygen protecting group when attached to an oxygen atom, or two instances of Ra are joined to form a substituted or unsubstituted, heterocyclic ring, or substituted or unsubstituted, heteroaryl ring.